- AC Immune (NASDAQ:ACIU) and WuXi Biologics (OTCPK:WXXWY) plan to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications.
- This next phase of the strategic partnership between the companies builds on the know-how of ACIU's drug discovery and development platforms and WuXi's expertise in manufacturing innovative biologics.
- A particular focus is developing AC Immune’s clinical antibody candidate to ensure it has high affinity for TDP-43 and is capable of preventing the intercellular spread of toxic species.
- Through the new agreement, the company gains access to WuXi Biologics’ proprietary platforms, including cell line development platform. AC Immune will retain all intellectual property rights to molecules.
- https://seekingalpha.com/news/3633437-ac-immune-and-wuxi-biologics-boost-development-of-tdpminus-43-antibodies
Monday, November 9, 2020
AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.